Lanthio Pharma Receives Dutch Government Loan Of Up To €3.6 Million To Develop Novel Therapy For Lung Fibrosis

GRONINGEN, The Netherlands--(BUSINESS WIRE)--Lanthio Pharma B.V., the biopharmaceutical company focused on discovering and developing lanthipeptides, announced today that it has been awarded an Innovation Credit loan of up to €3.6 million by Dutch Government agency RVO. The Innovation Credit loan will support the development of LP2, an innovative lanthipeptide for treatment of Idiopathic Pulmonary Fibrosis.

Help employers find you! Check out all the jobs and post your resume.